A comparison of 29 commercial serological kits (17 ELISAs and 12 ICTs) was carried out in France.
Depending on the type of analysis performed, 2 to 4 of the ELISAs presented an excellent performance. In contrast, only one of the 12 ICTs had an accuracy >90% [32]. A line assay using 6 recombinant proteins corresponding to virulence factors (CagA, VacA, GroEL, gGT, HcpC, and UreA) was developed in Germany. It was validated on a group of 600 patients (42% H. pylori positive by histology) and showed 97.6% sensitivity and 96.2% specificity, that is, an improvement on currently available serological tests [33]. The same group in collaboration with researchers in Iran was able to identify a H. pylori protein, FliD, essential in the Pexidartinib molecular weight assembly of the flagella. The recombinant FliD protein was tested on a group of 618 patients (51.4% H. pylori positive) with 97.4% sensitivity and 99% specificity using a line assay, and 97 and 96% by ELISA, respectively [34]. Other attempts to select antigenic proteins of potential diagnostic value were made (CafI, ureG, ureB), but have not been evaluated yet [35]. Interestingly, using
Helicoblot 2.1 (Genelabs Diagnostics, Singapore), it was possible to identify a low molecular weight protein (35KDa) associated with a low risk of GC (OR = 0.4, 95% CI:0.1–0.9) and the VacA protein associated with a high risk of GC (OR = 2.7, 95 CI:1–7.1) among patients with GC (102) and dyspepsia (122) in Iran [36]. A review on ICTs was also produced last year [37]. Pepsinogen Selumetinib chemical structure I and II and their ratio as predictors of atrophy were evaluated this year in Iran [38], Turkey [39], and Italy [40], but they were found to be insensitive predictors of these Vildagliptin lesions. A toll-like receptor 4 was found helpful to differentiate between dysplasia and other precancerous lesions [39]. Both miR-106b and miR-21 were found as markers of increased risk for GC after H. pylori eradication [41]. The progress in imaging techniques allows now to have a more accurate approach of
the features associated to H. pylori infection. There are continuous attempts to improve the existing diagnostic methods or to evaluate their use in real life. Competing interest: The authors have no competing interests. “
“Background: A remarkable variety of restriction-modification (R-M) systems is found in Helicobacter pylori. Since they encompass a large portion of the strain-specific H. pylori genes and therefore contribute to genetic variability, they are suggested to have an impact on disease outcome. Type I R-M systems comprise three different subunits and are the most complex of the three types of R-M systems. Aims: We investigated the genetic diversity and distribution of type I R-M systems in clinical isolates of H. pylori. Material and methods: Sixty-one H. pylori isolates from a Swedish hospital based case-control study and 6 H.